Aviragen Therapeutics Licenses Georgia State Technology to Develop Antiviral Therapies

ATLANTA—The Georgia State University Research Foundation (GSURF) has entered into a licensing and sponsored research agreement with Aviragen Therapeutics, Inc., a Georgia-based pharmaceutical company developing the next generation of antivirals, to develop and commercialize respiratory syncytial virus (RSV) replication inhibitors.

RSV infection is the leading cause of virus-induced death among children below one year of… more »

Nanoparticles Show Promise for Treating Intestinal Inflammation, Biomedical Research Study Finds

ATLANTA—Nanoparticles designed to block a cell-surface molecule that plays a key role in inflammation could be a safe treatment for inflammatory bowel disease (IBD), according to researchers in the Institute for Biomedical Sciences at Georgia State University and Southwest University in China.

The scientists developed nanoparticles, or microscopic particles, to reduce the expression of… more »

Leading Virologist Chris Basler Named Founding Director of Center for Microbial Pathogenesis

ATLANTA—Dr. Chris Basler, a world-renowned research leader in the study of emerging viruses, including the Ebola virus, has been named founding director of the Center for Microbial Pathogenesis, Institute for Biomedical Sciences (IBMS), at Georgia State University.

Recruited from Icahn School of Medicine at Mount Sinai in New York, Basler joins Georgia State… more »